ERBB2 and neoplasm: While traditional anti-HER2 monoclonal antibodies act by blocking aberrant HER2 signalling via dimerisation inhibition, HER2 internalisation, and potent antibody-dependent cellular cytotoxicity, ADCs are designed to target tumour cells and cause cell death by delivering cytotoxic chemotherapy directly.